New brain scan method aims to spot Alzheimer's and Parkinson's early
NCT ID NCT06080659
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a new, low-cost type of brain scan can find early signs of Alzheimer's and Parkinson's disease. Researchers will compare brain scans from 120 people, including those at risk for Alzheimer's, those with Parkinson's, and healthy volunteers. The goal is to see if these scans can serve as a simple, non-invasive biomarker for early diagnosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2023
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * For all participants: * French mother tongue * right-handed * with a level of education equal to or higher than the Certificat d'Études Primaires (Primary School Certificate) * Free of any medical or psychiatric condition likely to interfere with cognition (excluding diagnosis for patients) * Affiliated with a social security scheme * Having received oral and written information about the protocol and having signed a consent form to participate in this research. DCS+ group: \- Meeting the diagnostic criteria for "subjective cognitive decline-plus" (Jessen criteria (Jessen et al., 2014). Alzheimer's patients "Mild Cognitive Impairment due to Alzheimer's Disease," "MCI-MA": \- Meeting the diagnostic criteria for "Mild neurocognitive disorder due to Alzheimer's disease" (criteria of (Albert et al., 2011)) De novo" Parkinsonian patients, "MPdn": \- Presenting with newly diagnosed ("de novo") Parkinson's disease and free of cognitive deficits (criteria of Postuma et al., 2015 (Postuma et al., 2015)) Parkinsonian patients with "Mild Cognitive Impairment, "MCI-MP": \- Presenting Parkinson's disease associated with "mild neurocognitive impairment" (criteria of Litvan et al., 2012 (Litvan et al., 2012)) Exclusion Criteria: * All participants (healthy volunteers and patients) * Contraindications to MRI : * Abdominal circumference + upper limbs sticking to the body \> 200 cm; * Implantable pacemaker or defibrillator; * Neurosurgical clips; * Cochlear implants ; * Neural or peripheral stimulator; * Intra-orbital or encephalic metallic foreign bodies; * Endoprostheses fitted less than 4 weeks ago and osteosynthesis devices fitted less than 6 weeks ago; * Claustrophobia. * Pregnant or breast-feeding women; * Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty. Patients only * Score \>2 on the modified Hachinski scale (Hachinski et al., 2012) * Dementia according to McKhann criteria (McKhann et al., 2011) * Sensory deficit interfering with experimental tests Healthy volunteers only \- Cognitive impairment (MoCA score \< 26)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease, early onset are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU Rennes
RECRUITINGRennes, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Giving Parkinson's patients a say may boost their Brain's ability to learn movement
- Brain scans probe why some Parkinson's patients freeze Mid-Step
- Can tango rewire the brain? dance program tested for Parkinson's and dementia
- Can a workout after walking practice help Parkinson's patients learn better?